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ABSTRACT EvidencehasrecentlyaccumulatedsuggestingthatsmallnoncodingRNAs,andparticularlymicroRNAs,havethepo-
tentialtostronglyaffectthereplicationandpathogenicpotentialofarangeofhumanvirusspecies.Here,wereporttheuseof
deepsequencingtocomprehensivelyanalyzesmallviralRNAs(18to27nucleotides[nt])producedduringinfectionbyinﬂuenza
Avirus.AlthoughinﬂuenzaAvirusdiffersfrommostotherRNAvirusesinthatitreplicatesitsgenomeinthenucleusandis
thereforeexposedtothenuclearmicroRNAprocessingfactorsDroshaandDGCR8,wedidnotobserveanymicroRNAsencoded
byinﬂuenzavirusgenes.However,inﬂuenzavirusinfectiondidinducetheexpressionofveryhighlevels—over100,000copies
percellby8hpostinfection—ofapopulationof18-to27-ntsmallviralleaderRNAs(leRNAs)thatoriginatedfromtheprecise
5=endsofalleightinﬂuenzavirusgenomicRNA(vRNA)segments.LikethevRNAsthemselves,ourdataindicatethattheleRNAs
alsobeara5=-terminaltriphosphateandarethereforenotcapableoffunctioningasmicroRNAs.Instead,thehigh-levelproduc-
tionofleRNAsmayimplyaroleinanotheraspectofthevirallifecycle,suchasregulationoftheswitchfromviralmRNAtran-
scriptiontogenomicRNAsynthesis.
IMPORTANCE InﬂuenzaAvirusisanimportanthumanpathogenthathasthepotentialtogiverisetoseriouspandemics.Here,we
demonstratethatinﬂuenzaAvirusinducestheexpressionofveryhighlevelsofsmallviralleaderRNAs(leRNAs)withinhoursof
infection.TheseRNAsareunusualinthattheybeara5=triphosphateandoriginatefromthevery5=endsoftheeightviral
genomicRNA(vRNA)segments.Theirhighexpressionmayimplyanimportantroleinthevirallifecyclethatcouldpotentially
serveasanoveltargetforantiviraldrugs.
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M
icroRNAs (miRNAs) are small regulatory RNAs of ~22 nu-
cleotides(nt)inlengththatareexpressedbyallmulticellular
eukaryotes (1). The large majority of miRNAs are initially tran-
scribed as part of a long capped, polyadenylated transcript re-
ferredtoasaprimarymiRNA(pri-miRNA)precursor,wherethey
form part of one arm of an internal ~80-nt stem-loop (2). This
stem-loop is recognized by the nuclear RNase III enzyme Drosha,
acting in concert with its cofactor DGCR8, leading to cleavage of
thepri-miRNAstem.Thiscleavageliberatesan~60-ntRNAhair-
pinbearingan~2-nt3=overhang,calledthepre-miRNAinterme-
diate. After nuclear export, the pre-miRNA encounters the cyto-
plasmicRNaseIIIenzymeDicer,whichremovestheterminalloop
of the pre-miRNA, leaving a second ~2-nt 3= overhang. One
strand of the resultant miRNA duplex intermediate is then incor-
poratedintotheRNA-inducedsilencingcomplex(RISC),whereit
acts as a guide RNA to direct RISC to mRNA species bearing a
complementary sequence. Binding of RISC to mRNA target se-
quencesresultsininhibitionofproteinsynthesisandsomedegree
of destabilization (1). It should be noted that both Drosha and
Dicer leave a 5= monophosphate after RNA cleavage and that this
5= phosphate is, in fact, critical for miRNA incorporation into
RISC (1, 3, 4).
It has recently become increasingly clear that miRNAs can ex-
ert a major positive or negative effect on viral replication (5). In
particular,ithasnowbeendemonstratedthatanumberofnuclear
DNAvirusescarrygenesthatencodemiRNAsthatappearlikelyto
playanimportantroleinpromotingviralpathogenesis(6–13).In
contrast, analysis of a range of RNA viruses has failed to identify
any miRNAs encoded by viral genes (9, 14, 42). At least two rea-
sons for the current lack of RNA virus-derived miRNAs are ap-
parent. On the one hand, excision of a viral miRNA from the
genome or antigenome of an RNA virus would result in their
cleavage and degradation, which is likely to be disadvantageous.
On the other hand, it is also true that almost all the RNA viruses
examined thus far replicate in the cytoplasm, away from the nu-
clear Drosha/DGCR8 heterodimer that initiates miRNA process-
ing.Ifthisisthekeyconsideration,thenRNAvirusesthatreplicate
inthenucleus,unlikeRNAvirusesthatreplicateinthecytoplasm,
might express one or more viral miRNAs in infected cells. In the
case of the retroviruses HIV-1 and human T-cell leukemia virus
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these nuclear RNA viruses do not, in fact, contain genes that en-
codeanymiRNAs,althoughthisissuehasremainedcontroversial
(9, 14–16).
Another prominent RNA virus family that replicates its ge-
nome in the nucleus is the Orthomyxoviridae and, in particular,
inﬂuenza A virus. Inﬂuenza A virus is a segmented, negative-
strand RNA virus, and its polymerase complex (composed of the
PB2, PB1, and PA proteins) generates not only mRNAs but also
viral genomic RNAs (vRNAs) and plus-sense intermediates in
vRNA biogenesis, called cRNAs, during infection (17). All these
RNAsarederivedfromtheeightvRNAsegmentsthatenterthecell
in the infecting virus particle and that then rapidly migrate into
the nucleus. We were therefore curious to determine whether in-
ﬂuenza A virus might contain genes that encode miRNAs within
one or more of its genomic vRNA segments or in the plus-sense
viral mRNAs or cRNAs.
Using deep sequencing, we demonstrate that inﬂuenza virus
does not express any viral miRNAs but instead generates high
levelsof~18-to27-ntsmallviralleaderRNAs(leRNAs)thatorig-
inate from the very 5= end of each of the eight vRNA segments.
These leRNAs accumulate to high levels in inﬂuenza virus-
infected cells, reaching 100,000 copies per cell by 8 h postinfec-
tion (hpi), a level substantially higher than the total number of
cellular miRNAs. Moreover, leRNAs differ from miRNAs both in
their relatively heterogeneous lengths and, more importantly, in
the fact that they retain a 5= triphosphate, which precludes their
incorporation into RISC (1, 3, 4). The high level of expression of
the leRNAs is consistent with their playing an important role in
the inﬂuenza virus life cycle.
RESULTS
To determine whether inﬂuenza A virus expresses miRNAs or
other small viral RNAs in infected cells, we infected the highly
permissive Madin-Darby canine kidney (MDCK) cell line at a
multiplicityofinfection(MOI)of2percellwiththehumanH3N2
inﬂuenza virus isolate A/Wuhan/359/95 (18). To minimize cyto-
pathiceffects,whichcouldinducetheproductionofcellularRNA
breakdown products, we chose to harvest total cellular RNA at 8
hpi, by which point the viral titer has plateaued, yet no cytopathic
effect was apparent (18). As our initial focus was on miRNAs
potentiallyencodedbyviralgenes,weusedapreviouslydescribed
cDNAsynthesisprotocolthatdirectlyligates3=andthen5=adapt-
ers onto small (~18- to 30-nt) RNAs puriﬁed from the total RNA
pool (9, 13). As a result, this cDNA synthesis protocol is depen-
dent on the presence of a 5= phosphate, which is typical of
miRNAs,butexcludesRNAsbearingother5=modiﬁcations,such
as a triphosphate or a cap.
This initial effort resulted in 135,408 usable Solexa sequence
reads of 18 to 27 nt in length, of which the majority (~79%) were
known cellular miRNAs that are conserved in humans and other
mammalian species, including canines (Table 1). This number
likely underestimates the number of cellular miRNAs, as canine
miRNAshavenotyetbeenwellcharacterized.Inaddition,wealso
recovered654sequencereads(~0.5%)thatwereofinﬂuenzavirus
origin. Interestingly, the large majority of these reads (550 of 654,
or ~0.4% of the total reads obtained) originated from the exact 5=
end, or very near the 5= end, of each of the eight inﬂuenza virus
vRNA segments. To further examine whether this represented a
discrete population of viral small RNAs, we next performed a
Northern blot analysis using a mixture of four oligonucleotide
probes speciﬁc for the 5= ends of the PB1, M, NA, and NP vRNA
segments. This experiment (Fig. 1) resulted in the detection of a
very strong RNA signal in the 20- to 30-nt range in inﬂuenza
virus-infected MDCK cells that was not present in uninfected
cells.
A highly expressed population of inﬂuenza virus leader
RNAs. The cDNA synthesis protocol used to generate the ﬁrst
small RNA sequence library from inﬂuenza virus-infected cells is
notabletocaptureRNAsbearing5=triphosphates,sothefactthat
the majority of the inﬂuenza virus RNAs recovered were derived
from the 5= ends of the inﬂuenza vRNA segments, which bear a
terminal triphosphate (17), was unexpected. Moreover, given the
low level of recovery of these leRNAs, 0.5% of the total number
of small RNAs sequenced, the intensity of the signal detected by
Northern analysis for these same leRNAs was also not anticipated
(Fig. 1). We therefore reasoned that there might be a high level of
expressionofviralsmallRNAsoriginatingfromthe5=endsofthe
eight vRNAs in inﬂuenza virus-infected cells that was not cap-
TABLE 1 Characterization of two inﬂuenza virus-infected small RNA
cDNA libraries
Characteristic Value (%) for characteristic
Library 1a Library 2b
Total no. of reads 135,408 5,365,655
No. of inﬂuenza readsc 654 (~0.5) 1,792,020 (~33)
No. of cellular miRNAsd 107,106 (~79) 1,029,813 (~19)
No. of other readse 27,648 (~20) 2,543,822 (~47)
a Library 1 utilized a cDNA synthesis protocol that captures only small (18- to 27-nt)
RNAs bearing a 5= monophosphate.
b Library 2 used the same total RNA preparation but utilized a cDNA synthesis protocol
that captures small RNAs regardless of their 5= phosphorylation status.
c Inﬂuenza reads are reads that map anywhere on the inﬂuenza virus genome.
d Cellular miRNAs refers to reads that are homologous to known human miRNAs
(miRBase version 15.0).
e “Other reads” refers to reads that represent mRNA, rRNA, etc., breakdown products
or that could not be assigned.
FIG1 NorthernblotanalysisofinﬂuenzavirusleaderRNAexpression.Total
RNA was isolated 8 hpi from MDCK cells infected with the H3N2 inﬂuenza
virus isolate A/Wuhan/359/95 and analyzed using a pool of oligonucleotide
probes designed to recognize the 5= 18 nt of the PB1, NA, M, and NP vRNAs.
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would contain only rare 5=-terminal inﬂuenza vRNA fragments
that had undergone partial hydrolysis in the cells, or during RNA
isolation, to leave a 5= monophosphate.
To address this issue, we therefore generated a second small
RNA library, using the same inﬂuenza virus-infected cell total
RNA preparation, that included a step whereby all 5= phosphates
were ﬁrst removed by incubation with alkaline phosphatase, fol-
lowed by addition of a single 5= phosphate using polynucleotide
kinase (PNK). The advantage of this modiﬁed technique is that it
would allow us to recover any viral RNAs bearing a 5= triphos-
phate in this second cDNA library. The disadvantage is that we
would also recover common RNA breakdown products lacking
any 5= phosphate moieties.
Solexa deep sequencing of this second small RNA library
yielded5,365,655usablereadsof18to27ntinlength(Table1).Of
these, 2,543,822 (~47%) represented RNA breakdown products
(cellular mRNA, rRNA, tRNA, snRNA, etc.) or were not assign-
able, a substantially higher percentage than seen with library 1
(Table 1). On the other hand, we recovered only 1,029,813 iden-
tiﬁable canine cellular miRNA reads in library 2, which repre-
sented ~19% of the total number of reads, far less than the ~79%
seen in library 1. Most strikingly, the number of inﬂuenza virus
reads increased from ~0.5% (654) to ~33% (1,792,020) of the
totalnumberofreads.Analysisofthegenomicoriginoftheseviral
small RNAs revealed that, overall, 98.4% coincided with the pre-
cise5=endofeachoftheeightvRNAsegments,varyingfromalow
of97.3%inthecaseofthePB2vRNAtoahighof99.6%fortheNA
segment(Table2).Intermsofsegmentorigin,werecoveredalow
of 63,435 leRNAs derived from the NS segment to a high of
562,102 derived from PB2 (Table 2). By analogy to the small,
5=-triphosphorylatedviralleaderRNAsthathavebeenreportedin
cells infected by other negative-strand RNA viruses (19–23), we
refertoinﬂuenzavirussmallRNAsthatoriginatefromthe5=ends
of the vRNA segments as inﬂuenza virus leader RNAs (leRNAs).
Analysis of the size distribution of the 18- to 27-nt cellular
small RNAs in library 2 (Fig. 2A) revealed that the total cellular
smallRNApopulation,whichrepresentsamixtureofRNAbreak-
downproductsandcellularmiRNAs,washeterogeneousinlength
butwithaclearpeakatthepredicted22-or23-ntsizeexpectedfor
miRNAs (1), even though miRNAs appear to represent only a
small proportion of these cellular RNA sequences (Table 1). (The
peak at 23 nt reﬂects the very high level of expression of a 23-nt
isoformofmiR-21inMDCKcells.)Incontrast,theinﬂuenzavirus
leRNAs showed no clear size preference, although 19-nt, 21-nt,
and 22-nt species were slightly predominant (Fig. 2B). Further
breakdown of the leRNA size distribution by viral segment of or-
igin(Table3)againshowednoparticularsizepreference,withthe
most common size varying from 19 nt (PB2, M, NS, and HA) to
25 nt (PB1), with substantial numbers recovered at all sizes be-
tween the 18-nt and 27-nt cutoffs. (Due to technical limitations
intrinsictotheSolexasequencingprotocol,RNAsof28ntinsize
could not be unequivocally identiﬁed.) The absence of tight clus-
teringoftheleRNAsatthe22/23-ntsizecharacteristicofmiRNAs
isexpected,asourdatastronglysuggestthattheleRNAscontaina
5=-terminal triphosphate, which would preclude incorporation
into RISC.
We also recovered a small number of inﬂuenza virus RNA
fragments (28,292) that originate from regions of the inﬂuenza
virus genome other than the 5= ends of vRNAs. Could these rep-
resent viral miRNAs? In fact, analysis of their size distribution
againrevealednopreferenceforthe22/23-ntsizecharacteristicof
miRNAs(Fig.2C).Analysisofthepreciseoriginofallsmallinﬂu-
TABLE 2 Percentage of leader RNAs compared to all inﬂuenza virus-
derived sequencesa
Gene No. of inﬂuenza virus RNAs No. of leRNAs % of leRNAs
PB2 577,849 562,102 97.3
PB1 195,040 192,073 98.5
PA 378,204 373,593 98.8
HA 72,844 72,085 99.0
NP 283,744 282,006 99.4
NA 113,579 113,167 99.6
M 106,629 105,270 98.7
NS 64,134 63,435 98.9
Overall 1,792,020 1,763,730 98.4
a This table presents the number and percentage of small inﬂuenza virus RNAs that
start at position 1 of each vRNA segment, deﬁned as leader RNAs (leRNAs).
FIG 2 Size distribution of small RNAs returned by Solexa/Illumina deep
sequencing.(A)Sizedistributionofallnon-inﬂuenzavirussmallRNAsrecov-
ered in library 2 (Table 1). (B) Size distribution of all inﬂuenza virus small
RNAs. (C) Size distribution of all non-leRNA inﬂuenza virus small RNAs.
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segments of inﬂuenza virus (Fig. 3) revealed the expected high
level of origin from the 5= ends of the vRNA segments that is the
deﬁning characteristic of inﬂuenza virus leRNAs and also showed
amodestenrichmentofinﬂuenzavirussmallRNAsfromnearthe
3=endofthevRNA,aswellasfromthe3=endofthemRNA/cRNA
population,althoughtheseareallpresentatalevelthatis1,000-
foldlowerthanthelevelofleRNAs.Otherinﬂuenzavirus-derived
small RNAs were derived from random locations within both the
vRNA and mRNA/cRNA transcripts, and not from one or a small
number of discrete sites, as would be predicted for miRNAs
(Fig. 3). Instead, this distribution suggests that these are random
viral RNA breakdown products.
Inﬂuenza virus leader RNAs are expressed early after infec-
tion. After infection by inﬂuenza virus, the eight vRNA segments
areinitiallycopiedtoyieldviralmRNAspeciesthatarethentrans-
lated to yield viral proteins (17). These newly synthesized inﬂu-
enza virus proteins, in particular the viral nucleoprotein NP, are
thenthoughttoinduceapartialswitchfrommRNAtranscription
to genome replication, i.e., to cRNA synthesis followed by the
generationofnewvRNAs,beginningat1or2hoursafterinfection
(24–26).IthasbeenproposedthattheseprogenyvRNAscanmake
asigniﬁcantcontributiontoviralmRNA,andhenceprotein,syn-
thesis, although this has remained controversial (25, 27, 28).
The leRNAs we observe must be derived from transcripts cop-
ied from viral cRNAs and are likely to result from nonprocessive
transcription of the 3= ends of the cRNAs or, less probably, from
endonucleolytic cleavage of vRNA transcripts. In either case, one
might expect leRNA expression to occur somewhat later in the
viral life cycle. To address this issue, we performed a time course
analysis of leRNA production in MDCK cells infected with either
theH3N2virusisolateA/Wuhan/359/95(18)oranH1N1clinical
isolate, A/HK/54/98 (29), at a multiplicity of infection (MOI) of
~2/cell (Fig. 4A and B). Interestingly, we observed that the H3N2
virus gave rise to detectable leRNA expression as soon as 2 hpi,
whichincreasedrapidlyupto8hpi.Thepatternobservedwiththe
more cytopathic H1N1 isolate was slightly different, with leRNA
expression being ﬁrst detected at ~4 hpi and then increasing rap-
idly to 6 hpi. We also noted some differences in leRNA size, with
the H3N2 isolate giving rise to leRNAs that were essentially all
between20and30ntinsize(Fig.4A),whiletheH1N1isolategave
rise to some leRNAs that appeared to be slightly over 30 nt, al-
though leRNAs 20 to 30 nt in size again predominated (Fig. 4B).
To extend these data to a third inﬂuenza virus isolate and to a
second cell line, we harvested total RNA samples from human
293T cells infected with the H3N2 inﬂuenza virus isolate
A/Udorn/72 (30) at an MOI of ~1. The assay used to quantify
leRNA expression in this instance was quantitative reverse tran-
scriptase PCR (qRT-PCR), using a stem-loop probe speciﬁc for
the PB2 leRNA, which was expected to allow detection of the
leRNAs over a wide dynamic range. As shown in Fig. 4C, we were
againabletodetectleRNAsassoonas2hpi,butwenowobserved
that the leRNAs continued to accumulate up to 36 hpi. Overall,
these data suggest that leRNAs and vRNAs are likely to arise si-
multaneously and quite early in the inﬂuenza virus life cycle and
also suggest that the leRNAs, like the full-length vRNAs, accumu-
late in infected cells and can reach high levels at late times after
infection. We note that previous reports have demonstrated that
vRNA synthesis can initiate as soon as 1 hpi (25).
DISCUSSION
The initial goal of this research project was to determine whether
inﬂuenza A virus, which copies its RNA genome in the nucleus,
might give rise to viral miRNAs. Unexpectedly, we instead ob-
served that inﬂuenza virus generates very high levels of short (18-
to27-nt-long)viralleaderRNAs(leRNAs)thatoriginatefromthe
very5=endsofalleightvRNAsegments.Ourdatastronglysuggest
that these leRNAs, like the vRNAs themselves, contain a 5=-
terminaltriphosphate.Asaresult,theleRNAswererecoveredvery
inefﬁciently when a standard small RNA sequencing protocol,
which requires a 5= phosphate, was used. However, leRNAs be-
came the dominant small RNA species when a modiﬁed protocol
was used; the modiﬁed protocol allows the generation of cDNAs
from small RNAs regardless of the 5= phosphorylation status (Ta-
ble 1). Remarkably, under these conditions, we recovered sub-
stantially more leRNAs from cells infected 8 h previously with
inﬂuenza A virus than total cellular miRNAs. As individual cells
generally express from 80,000 to over 100,000 miRNAs (1), this
means that inﬂuenza leRNAs were expressed at well over 100,000
copies per cell by 8 hpi.
Because miRNA incorporation into RISC requires a 5= mono-
phosphate (1, 3, 4), the leRNAs we detected cannot represent
TABLE 3 Size distribution of H3N2 leader RNAsa
Length (nt) No. of leRNAs of the indicated length derived from the following inﬂuenza vRNA segment:
PB2 PB1 PA HA NP NA M NS
18 33,567 8,512 15,097 6,858b 4,498 14,251 7,049 6,858b
19 115,343 10,093 15,888 15,330b 13,470 6,462 28,056 15,330b
20 36,539 18,962 34,487 3,742b 24,710 21,361 9,064 3,742b
21 70,309 28,898 70,226 7,308b 42,140 9,728 26,498 7,308b
22 82,197 12,056 105,011 7,526 46,306 8,184 16,255 5,247
23 22,272 20,949 63,814 2,878 48,082 15,643 11,174 6,664
24 42,376 16,307 26,101 5,006 42,786 14,607 1,500 2,296
25 32,327 34,429 24,996 14,640 42,608 15,033 2,002 7,152
26 75,262 32,694 8,399 5,673 12,353 3,100 3,346 5,094
27 51,910 9,173 9,574 3,125 5,053 4,798 326 3,745
Total 562,102 192,073 373,593 72,085 282,006 113,167 105,270 63,435
a This table presents the size distribution, in nucleotides, of the leRNAs derived from each of the indicated inﬂuenza vRNA segments, with the most prevalent size in boldface type.
b Because the HA and NS vRNAs are identical in sequence through nucleotide 21, we could not assign reads derived from these sequences unequivocally. We have therefore
arbitrarily assigned 50% of the reads to each of these two segments.
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leaves behind a 5= monophosphate (1), these RNase III enzymes
are clearly not involved in leRNA biogenesis. Most probably, the
leRNAs result from premature termination by the viral RNA-
dependent RNA polymerase (RdRP) while utilizing a cRNA tem-
plate. While this has been previously reported to occur at high
FIG 3 Genomic origin of all inﬂuenza virus small RNAs. Small red circles indicate the frequency and genomic locations of the starting nucleotide of
vRNA-derived sequences recovered by deep sequencing, while small green circles represent the frequency and genomic locations of mRNA/cRNA-derived
sequencesforalleightinﬂuenzavirusgenomesegments.TheviralleRNAs,whichstartatnucleotide1ofthevRNA,areindicatedbyalargeredcirclecontaining
a small red circle. The data used were derived from cDNA library 2 (Table 1). All sequences are aligned on the basis of their 5= ends, which are aligned to the left
for the vRNAs and to the right for the viral cRNAs/mRNAs. The frequency is the number of viral sequence reads obtained that bear identical 5= ends.
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leRNAs instead arise from endonucleolytic cleavage of nascent or
mature vRNA molecules. The heterogeneous 3= ends of the
leRNAs (Table 3) would appear to make the latter hypothesis less
likely.
While leRNAs account for 98.4% of all small inﬂuenza viral
RNAs, we did detect small RNAs that were derived from regions
other than the precise 5= ends of the vRNAs. However, these in-
ﬂuenzavirussmallRNAsdidnotshowadiscretesizeof~22nt,as
predicted for both miRNAs and small interfering RNAs (siRNAs)
(Fig. 2C) (1), and are therefore likely RNA breakdown products.
Consistent with this hypothesis, these small viral RNAs were not
derived from discrete locations within the inﬂuenza virus
genomic segments, as would be expected for viral miRNAs
(Fig. 3).
It is interesting to compare our observations with previously
published work documenting the expression of short leader
RNAs, derived from the 5= ends of the genomic RNA, in cells
infected with a range of other negative-strand RNA viruses, in-
cludingvesicularstomatitisvirus(VSV)(21,23),rabiesvirus(22),
and respiratory syncytial virus (19). The most studied of these are
theVSVleRNAs,whichcontaina5=-terminaltriphosphate,range
from ~44 to ~54 nt in length, and have been reported to be ex-
pressed at ~300 copies per infected cell (20, 32, 33). Despite their
very low level of expression, the VSV leRNAs have been proposed
toplayakeyroleintheVSVlifecyclebyregulatingtheswitchfrom
mRNA transcription to genomic RNA replication by binding to
the VSV nucleocapsid protein (20). The VSV leRNAs have also
been shown to bind the cellular protein La (33, 34), which may
preventactivationofthecellularinnateimmunityfactorRIG-Iby
these 5=-triphosphorylated RNA molecules (19).
Whilethisarticlewasbeingprepared,Perezetal.(35)reported
the expression of analogous inﬂuenza virus leader RNAs, which
they termed small viral RNAs, in a range of inﬂuenza virus-
infected cell types, including human lung epithelial cells and em-
bryonated chicken eggs. These small viral RNAs were initially de-
tected by conventional deep sequencing, using a protocol that
captures only small RNAs bearing a 5= monophosphate, and as a
result, the small viral RNAs comprised only 1,524 (0.04%) of the
total of 4,217,121 short RNA sequence reads reported by this
group. This is comparable to, but even lower than, the ~0.4% of
total sequence reads contributed by the leRNAs when we used a
comparable sequencing protocol and contrasts with the very high
level of leRNAs that were detected when a protocol that captures
5=-triphosphorylated short RNAs was used (Table 1).
Perezetal.(35)reportedthattheirinﬂuenzavirussmallRNAs
were between 22 and 27 nt in length and were derived from the 5=
endsofalleightinﬂuenzavirusgenomesegments,whichissimilar
to what we have observed for the leRNAs (Fig. 2B and Table 3),
although it is also clear that the leRNAs bear fairly heterogeneous
3=ends.OurdatadodiffersomewhatfromPerezetal.(35)inthat
theseauthorsreportedthattheirsmallviralRNAsweredetectable
startingat~12hpi,whilewecouldclearlyseeleRNAexpressionat
6hpiandsometimesevenearlier(Fig.4).Indeed,by8hpi,leRNAs
werefoundtobeexpressedat105copiespercell,asnotedabove.
This discrepancy may result from the use of different cell types in
these analyses, as Perez et al. (35) primarily used A549 cells, while
we primarily used MDCK cells.
An important observation reported by Perez et al. (35) is that
introduction of an antisense locked nucleic acid (LNA) oligonu-
cleotide (36) complementary to the HA segment leRNA inhibits
HA vRNA synthesis yet had little or no effect on HA mRNA or
cRNA transcription, thus suggesting that leRNAs might play a
criticalroleinvirusgenomereplication,perhapsbytriggeringthe
switch from mRNA transcription to genome replication. This re-
sultisperhapsunexpected,asithaspreviouslybeenproposedthat
productionofoptimallevelsofinﬂuenzavirusmRNAs,andhence
proteins, requires mRNAs generated by transcription of newly
generated vRNAs, not just mRNAs transcribed from the input
virus vRNA genomes (25, 28, 31). If this hypothesis is indeed
correct, then loss of leRNA function should inhibit not only
vRNA, but also mRNA, synthesis, which was not observed (35).
WenotethattheLNAusedinthisexperimenthasthepotentialto
anneal to not only the HA leRNAs but also to the identical vRNA
5= ends present on both the input and newly generated HA vRNA
segments.Givendatashowingthatthe5=13ntorsoofthevRNAs
playsacriticalroleininﬂuenzavirustranscription(17,37),itmay
be difﬁcult to segregate phenotypic effects resulting from LNA
annealing to the viral leRNAs from effects resulting from LNA
annealing to the vRNAs themselves. Nevertheless, the hypothesis
that the inﬂuenza virus leRNAs play a critical role in the temporal
regulation of inﬂuenza virus RNA synthesis (35) is an important
one and certainly consistent with their very high level of expres-
sion. Moreover, the proposed role for leRNAs in the inﬂuenza
virus replication cycle is similar to that proposed for the viral
FIG 4 Time course analysis of inﬂuenza virus leader RNA expression. (A)
Northern analysis of RNA samples isolated from MDCK cells infected with
H3N2 isolate A/Wuhan/359/95 and harvested at the indicated time points,
given as hours postinfection (hpi) above the lanes. This Northern blot was
analyzed using the same leRNA-speciﬁc probes used in Fig. 1. (B) Expression
of H1N1 isolate A/HK/54/98-derived leRNAs in infected MDCK cells at the
indicated times postinfection. In panels A and B, the migration positions of
small RNA size markers are indicated to the right of the blots, and U6 RNA
served as a loading control. (C) qRT-PCR analysis of inﬂuenza virus leRNA
expression in 293T cells infected with the inﬂuenza virus isolate A/Udorn/72.
Samples were harvested at the indicated time points, given as hpi. The qRT-
PCR probe used is speciﬁc for leRNAs derived from the PB2 RNA segment.
Data are given as a multiple of the qRT-PCR signal obtained using mock-
infected cells, which was set at 1.
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in activating VSV genomic RNA replication (20). On the other
hand, it is also possible that the leRNAs simply represent pre-
maturelyterminatedvRNAtranscriptsand,therefore,donotreg-
ulate vRNA synthesis. On the basis of previous data obtained us-
ing other negative-strand RNA viruses, one could also envision
leRNAs playing a role in vRNA encapsidation into newly gener-
ated progeny virions (38) or in regulating innate immune re-
sponses(19,22,33,34).Inanycase,thehighlevelofexpressionof
viral leRNAs in inﬂuenza A virus-infected cells does suggest an
important role(s) in the virus replication cycle that could repre-
sent a novel target for the treatment of inﬂuenza virus-induced
disease.
MATERIALS AND METHODS
Cellculture,infections,andRNAisolation.Madin-Darbycaninekidney
(MDCK) cells were maintained in Eagle’s minimum essential medium
supplemented with 10% fetal bovine serum, nonessential amino acids,
and sodium pyruvate. Cells were infected with inﬂuenza virus at an MOI
of 2 and harvested at the indicated time points. Total RNA was harvested
using TriReagent according to the manufacturer’s protocol.
Solexa/Illumina deep sequencing. cDNA libraries for deep sequenc-
ingwerepreparedfromtotalRNAsamplesaspreviouslydescribed(9,13).
Brieﬂy,smallRNAs18to30ntinlengthwereisolatedfrom~30goftotal
RNAbygelfractionationandthensequentiallyligatedto3=and5=linkers.
cDNA libraries for deep sequencing were then generated by standard re-
versetranscriptionandPCRampliﬁcationoftheligatedsmallRNAs.Data
were returned in FASTA format and analyzed using custom scripts in
addition to the formatdb, megablast, blastoutparse, and ﬁlter alignment
scriptsofthemiRDeepsoftwarepackage(39).TocaptureallsmallRNAs,
regardless of their 5= phosphorylation status, additional dephosphoryla-
tionandkinasingstepswereincludedfollowingthe3=linkerligation,just
priortoligationofthe5=linker.Speciﬁcally,gel-puriﬁed3=linker-ligated
RNAs were dephosphorylated in a 20-l reaction mixture with 20 U of
alkaline phosphatase at 37°C for 1 h. Dephosphorylated RNAs were puri-
ﬁed by precipitation, and 5= monophosphates were added in a 20-l re-
actionmixturewith10UofT4PNKandanexcessofATPat37°Cfor1h.
All other aspects of sample preparation were identical to the standard
protocol (9, 13).
Northern blot analysis. leRNA expression was analyzed by standard
small RNA Northern blot analysis as previously described (6, 7). Brieﬂy,
30 g of total RNA was loaded onto 15% Tris-borate-EDTA (TBE)-urea
gels. RNAs were transferred onto nitrocellulose and ﬁxed by UV cross-
linking. The top portion of the blots, which contain the large viral RNAs,
were then removed to avoid titration of the pool of end-labeled probes
recognizing the PB1 (5=-AAAATGCCTTGTTTCTACT-3=), NA (5=-
AAACTCCTTGTTTCTACT-3=), M (5=-AACTACCTTGTTTCTACT-
3=), and NP (5=-AAATACCCTTGTTTCTACT-3=) leRNAs.
Quantitation of leRNA synthesis using qRT-PCR. Custom TaqMan
stem-loop primers from Applied Biosystems were designed against the
most common isoform of the PB2 leRNA recovered from deep sequenc-
ing (5=-AGUAGAAACAAGGUCGUUU-3=) and used to analyze RNA
harvestedfrominﬂuenzavirus-infectedcells,aspreviouslydescribed(40).
Brieﬂy,10ngoftotalRNAwasusedasatemplateforreversetranscription.
The sample was then diluted to 60 l, of which 8 l was used for PCR.
Values were normalized to a cellular miRNA, miR-16, and displayed as
fold expression relative to a mock-infected sample, as previously de-
scribed (41).
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